JP7237834B2 - 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療 - Google Patents

消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療 Download PDF

Info

Publication number
JP7237834B2
JP7237834B2 JP2019531756A JP2019531756A JP7237834B2 JP 7237834 B2 JP7237834 B2 JP 7237834B2 JP 2019531756 A JP2019531756 A JP 2019531756A JP 2019531756 A JP2019531756 A JP 2019531756A JP 7237834 B2 JP7237834 B2 JP 7237834B2
Authority
JP
Japan
Prior art keywords
ingestible device
ingestible
tract
subject
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020501699A5 (enExample
JP2020501699A (ja
Inventor
ミッチェル・ローレンス・ジョーンズ
シャラト・シン
クリストファー・ローレン・ウォール
ハリー・スティリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biora Therapeutics Inc
Original Assignee
Biora Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biora Therapeutics Inc filed Critical Biora Therapeutics Inc
Publication of JP2020501699A publication Critical patent/JP2020501699A/ja
Publication of JP2020501699A5 publication Critical patent/JP2020501699A5/ja
Priority to JP2023030863A priority Critical patent/JP2023071838A/ja
Application granted granted Critical
Publication of JP7237834B2 publication Critical patent/JP7237834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0097—Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0061—Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • A61B5/073—Intestinal transmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
JP2019531756A 2016-12-14 2017-12-14 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療 Active JP7237834B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023030863A JP2023071838A (ja) 2016-12-14 2023-03-01 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662434348P 2016-12-14 2016-12-14
US62/434,348 2016-12-14
US201762478744P 2017-03-30 2017-03-30
US62/478,744 2017-03-30
US201762545188P 2017-08-14 2017-08-14
US62/545,188 2017-08-14
US201762583797P 2017-11-09 2017-11-09
US62/583,797 2017-11-09
PCT/US2017/066474 WO2018112232A1 (en) 2016-12-14 2017-12-14 Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023030863A Division JP2023071838A (ja) 2016-12-14 2023-03-01 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療

Publications (3)

Publication Number Publication Date
JP2020501699A JP2020501699A (ja) 2020-01-23
JP2020501699A5 JP2020501699A5 (enExample) 2021-01-28
JP7237834B2 true JP7237834B2 (ja) 2023-03-13

Family

ID=60953956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531756A Active JP7237834B2 (ja) 2016-12-14 2017-12-14 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療
JP2023030863A Pending JP2023071838A (ja) 2016-12-14 2023-03-01 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023030863A Pending JP2023071838A (ja) 2016-12-14 2023-03-01 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療

Country Status (10)

Country Link
US (2) US11597762B2 (enExample)
EP (1) EP3554540B1 (enExample)
JP (2) JP7237834B2 (enExample)
KR (1) KR20190095931A (enExample)
CN (2) CN117045784A (enExample)
AU (1) AU2017376807B2 (enExample)
BR (1) BR112019011702A2 (enExample)
CA (1) CA3045475A1 (enExample)
MX (1) MX2019006823A (enExample)
WO (1) WO2018112232A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220135666A1 (en) * 2017-12-14 2022-05-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a s1p modulator
JP6611833B2 (ja) * 2018-01-16 2019-11-27 キヤノン株式会社 放射線撮影システム、並びに、カメラ制御装置及びその制御方法
EP3810268A1 (en) * 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
EP3883606B9 (en) * 2018-09-24 2024-11-20 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
AU2019378008A1 (en) * 2018-11-15 2021-06-03 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease
CN109350599A (zh) * 2018-12-12 2019-02-19 辽宁新高制药有限公司 一种用于皮肤念球菌病治疗的喷雾剂
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
JP2022552548A (ja) * 2019-10-18 2022-12-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
AU2020405301B2 (en) * 2019-12-16 2024-02-29 Eli Lilly And Company Capsule for gastrointestinal sampling
KR102391865B1 (ko) * 2020-04-03 2022-04-27 재단법인대구경북과학기술원 약물 전달 디바이스
EP4153220A4 (en) 2020-05-21 2024-09-11 Janssen Biotech, Inc. METHOD OF TREATING INFLAMMATORY BOWEL DISEASE BY MEANS OF COMBINATION THERAPY OF ANTIBODIES DIRECTED AGAINST IL-23 AND TNF ALPHA
CN112731954B (zh) * 2020-12-25 2024-06-21 深圳市优必选科技股份有限公司 机器人的运动控制方法、装置、机器人及存储介质
WO2022162149A1 (en) * 2021-01-29 2022-08-04 Biograil ApS Drug delivery device with releasable attachment part
WO2022162150A1 (en) * 2021-01-29 2022-08-04 Biograil ApS Single attachment part drug delivery device
DK180991B1 (en) * 2021-01-29 2022-09-06 Biograil ApS Drug delivery device with carrier and insert
EP4392095A1 (en) * 2021-10-28 2024-07-03 Biograil APS High-dose drug delivery device
EP4197437A1 (en) * 2021-12-17 2023-06-21 Stichting IMEC Nederland Methods and devices for in vivo assessment of analytes in the gastrointestinal tract
AU2023364486A1 (en) * 2022-10-17 2025-04-24 Rani Therapeutics, Llc Ustekinumab dosage forms and methods
CN116027048A (zh) * 2023-02-06 2023-04-28 山东中鸿特检生物科技有限公司 一种细胞因子风暴综合征诊断试剂盒及其应用
WO2025235985A1 (en) * 2024-05-10 2025-11-13 University Of Southern California Ingestible sensor or treatment system and method with localization from magnetic-field generating wearable device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502991A (ja) 1995-10-25 2000-03-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｉｌ−１２に対する抗体を使用する、確立した結腸炎を処置する方法
JP2006517827A (ja) 2003-01-29 2006-08-03 イー−ピル・ファーマ・リミテッド 胃腸管内における活性薬物の送達
WO2015059569A1 (en) 2013-09-26 2015-04-30 Medimetrics Personalized Drug Delivery, B.V. Delivery capsule with threshold release
WO2016049602A1 (en) 2014-09-25 2016-03-31 Progenity, Inc. Electromechanical pill device with localization capabilities
WO2016156465A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4281645A (en) 1977-06-28 1981-08-04 Duke University, Inc. Method and apparatus for monitoring metabolism in body organs
US4190328A (en) 1978-12-01 1980-02-26 Levine Robert A Process for detection of blood-borne parasites
JPS5588732A (en) 1978-12-26 1980-07-04 Olympus Optical Co Endoscope
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE69031919T3 (de) 1989-07-19 2005-01-27 Connetics Corp., Palo Alto T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5279607A (en) 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US5314805A (en) 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
US5318557A (en) 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999042838A1 (en) 1998-02-18 1999-08-26 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
US8440196B1 (en) 1998-08-24 2013-05-14 Chugai Seiyaku Kabushiki Kaisha Treatment for pancreatitis using IL-6 receptor antagonist antibodies
US6331530B1 (en) 1999-07-13 2001-12-18 The Trustees Of Columbia University In The City Of New York Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen
US6703248B1 (en) 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
GB9930000D0 (en) 1999-12-21 2000-02-09 Phaeton Research Ltd An ingestible device
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20030117491A1 (en) 2001-07-26 2003-06-26 Dov Avni Apparatus and method for controlling illumination in an in-vivo imaging device
US6949347B2 (en) 2002-03-05 2005-09-27 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
US7797033B2 (en) 2002-04-08 2010-09-14 Smart Pill Corporation Method of using, and determining location of, an ingestible capsule
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2525184C (en) 2003-05-09 2012-10-30 Centocor, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
WO2005000101A2 (en) 2003-06-12 2005-01-06 University Of Utah Research Foundation Apparatus, systems and methods for diagnosing carpal tunnel syndrome
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20050065441A1 (en) 2003-08-29 2005-03-24 Arkady Glukhovsky System, apparatus and method for measurement of motion parameters of an in-vivo device
JP4445732B2 (ja) 2003-08-29 2010-04-07 オリンパス株式会社 被検体内導入装置および無線型被検体内情報取得システム
JP2005074031A (ja) 2003-09-01 2005-03-24 Pentax Corp カプセル内視鏡
US20070059316A1 (en) 2003-09-23 2007-03-15 Pallenberg Alexander J Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents
US8206285B2 (en) 2003-12-31 2012-06-26 Given Imaging Ltd. Apparatus, system and method to indicate in-vivo device location
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
US7970455B2 (en) 2004-05-20 2011-06-28 Spectrum Dynamics Llc Ingestible device platform for the colon
WO2005113374A2 (en) 2004-05-21 2005-12-01 Given Imaging Ltd. Device, system and method for in-vivo sampling
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1841502A2 (en) * 2005-01-18 2007-10-10 Koninklijke Philips Electronics N.V. Electronically controlled capsule for releasing radiation
JP2008532568A (ja) * 2005-01-18 2008-08-21 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 電子制御されるカプセル
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
HRP20130400T1 (en) 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
US20070027362A1 (en) 2005-07-27 2007-02-01 Olympus Medical Systems Corp. Infrared observation system
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009541298A (ja) * 2006-06-20 2009-11-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 胃腸障害を処置するための電子カプセル
CN101472640B (zh) * 2006-06-23 2012-12-12 皇家飞利浦电子股份有限公司 药物输送系统
US20080112885A1 (en) 2006-09-06 2008-05-15 Innurvation, Inc. System and Method for Acoustic Data Transmission
WO2008053396A2 (en) 2006-10-31 2008-05-08 Koninklijke Philips Electronics N.V. Design of swallowable multi-nozzle, dosing device for releasing medicines in the gastrointesinal tract
US20100145301A1 (en) * 2007-02-26 2010-06-10 Duocure, Inc. Spray administration of compositions including active agents such as peptides to the gastrointestinal tract
MX2009009167A (es) * 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
CN101990429A (zh) * 2007-04-04 2011-03-23 希格默伊德药业有限公司 一种口服药物组合物
JP4932588B2 (ja) 2007-05-08 2012-05-16 オリンパス株式会社 画像処理装置および画像処理プログラム
US7842144B1 (en) 2007-06-01 2010-11-30 The United States Of America As Represented By The Secretary Of The Navy Methods of making double base casting powder
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
EP2244735A4 (en) 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
WO2009044774A1 (ja) 2007-10-02 2009-04-09 Chugai Seiyaku Kabushiki Kaisha インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
US20100331827A1 (en) 2008-02-18 2010-12-30 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
KR101361905B1 (ko) * 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR100931946B1 (ko) 2009-06-10 2009-12-15 주식회사 인트로메딕 캡슐 내시경에 의해 촬영된 이미지 데이터를 저장하고 있는 서버로부터 관심있는 데이터를 우선하여 단말기에 수신하여 확인할 수 있도록 하는 서버-클라이언트 시스템의 이미지 데이터 전송 프로세싱 방법
WO2011004395A1 (en) 2009-07-06 2011-01-13 Intas Biopharmaceuticals Limited Microemulsion formulation for biologicals
US20120136209A1 (en) 2009-08-05 2012-05-31 Tel Hashomer Medical Research Infrastructure And Services, Ltd. Methods and devices for providing information useful in the diagnosis of abnormalities of the gastrointestinal tract
US9026192B2 (en) 2009-11-24 2015-05-05 Given Imaging Ltd Device and method for in vivo imaging
US20130013031A1 (en) * 2010-03-17 2013-01-10 Photopill Medical Ltd. Capsule phototherapy
DE112012000404T5 (de) 2011-01-04 2014-04-17 Charitè Universitätsmedizin Berlin Modulatoren von IL-12 und/oder IL-23 zur Prävention oder Behandlung des Morbus Alzheimer
WO2012094623A2 (en) 2011-01-07 2012-07-12 Abbott Laboratories Anti-il-12/il-23 antibodies and uses thereof
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
JP5238100B2 (ja) 2011-04-01 2013-07-17 オリンパスメディカルシステムズ株式会社 受信装置及びカプセル型内視鏡システム
WO2012158648A1 (en) 2011-05-13 2012-11-22 Massachusetts Institute Of Technology Method and apparatus for delivering a substance
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
CA2857597A1 (en) 2011-11-30 2013-06-06 AbbVie Deutschland GmbH & Co. KG Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
JP2015509744A (ja) 2011-12-15 2015-04-02 ギブン イメージング リミテッドＧｉｖｅｎ Ｉｍａｇｉｎｇ Ｌｔｄ． 消化管内における出血のインビボ検出のための装置、システムおよび方法
US9795330B2 (en) 2011-12-15 2017-10-24 Given Imaging Ltd. Device, system and method for in-vivo detection of bleeding in the gastrointestinal tract
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
FR2986432B1 (fr) 2012-02-06 2014-03-14 Univ Lille Ii Droit & Sante Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17
EP3725234A1 (en) 2012-02-17 2020-10-21 Progenity, Inc. Ingestible medical device
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
RU2015155590A (ru) 2013-05-24 2017-06-29 Нестек С.А. Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника
US9324145B1 (en) 2013-08-08 2016-04-26 Given Imaging Ltd. System and method for detection of transitions in an image stream of the gastrointestinal tract
CN105848557B (zh) 2013-12-27 2018-09-28 王康怀 具有多光谱光源的胶囊摄影机装置
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
WO2015112575A1 (en) 2014-01-22 2015-07-30 The Board Of Regents Of The University Of Nebraska Gastrointestinal sensor implantation system
US10281017B2 (en) 2014-05-30 2019-05-07 Schaeffler Technologies AG & Co. KG Torque converter including spherical clutch
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
CN104473611B (zh) 2015-01-19 2018-01-30 吉林大学 具有超声波定位功能的胶囊内窥镜系统
US10064544B2 (en) 2015-01-26 2018-09-04 The Chinese University Of Hong Kong Endoscopic capsule and endoscopic system
US10773063B2 (en) 2015-05-31 2020-09-15 Check-Cap Ltd Drug delivery capsule
JP2017012395A (ja) 2015-06-30 2017-01-19 富士フイルム株式会社 内視鏡システム及び内視鏡システムの作動方法
CA3034263A1 (en) 2016-08-18 2018-02-22 Mitchell Lawrence Jones Sampling systems and related materials and methods
US20180070928A1 (en) 2016-09-09 2018-03-15 Progenity Inc. Systems and Methods for Extracting a Sample from an Ingestible Device
EP3509469A1 (en) 2016-09-09 2019-07-17 Progenity, Inc. Electromechanical ingestible device for delivery of a dispensable substance
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554333B1 (en) 2016-12-14 2023-08-23 Biora Therapeutics, Inc. Ingestible device recovery system
WO2018112389A1 (en) 2016-12-15 2018-06-21 Progenity Inc. Ingestible device and associated methods
CA3055762A1 (en) 2017-03-31 2018-10-04 Progenity, Inc. Localization systems and methods for an ingestible device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502991A (ja) 1995-10-25 2000-03-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｉｌ−１２に対する抗体を使用する、確立した結腸炎を処置する方法
JP2006517827A (ja) 2003-01-29 2006-08-03 イー−ピル・ファーマ・リミテッド 胃腸管内における活性薬物の送達
WO2015059569A1 (en) 2013-09-26 2015-04-30 Medimetrics Personalized Drug Delivery, B.V. Delivery capsule with threshold release
WO2016049602A1 (en) 2014-09-25 2016-03-31 Progenity, Inc. Electromechanical pill device with localization capabilities
WO2016156465A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides

Also Published As

Publication number Publication date
JP2023071838A (ja) 2023-05-23
CA3045475A1 (en) 2018-06-21
EP3554540C0 (en) 2023-08-02
CN110072551B (zh) 2023-05-23
US20250230229A1 (en) 2025-07-17
US11597762B2 (en) 2023-03-07
WO2018112232A1 (en) 2018-06-21
EP3554540A1 (en) 2019-10-23
MX2019006823A (es) 2019-10-21
AU2017376807A1 (en) 2019-06-13
EP3554540B1 (en) 2023-08-02
US20200262908A1 (en) 2020-08-20
CN117045784A (zh) 2023-11-14
CN110072551A (zh) 2019-07-30
JP2020501699A (ja) 2020-01-23
KR20190095931A (ko) 2019-08-16
BR112019011702A2 (pt) 2019-10-22
AU2017376807B2 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
JP7237834B2 (ja) 消化管疾病のｉｌ－１２／ｉｌ－２３阻害薬による治療
JP7150724B2 (ja) 消化管疾病のｔｎｆ阻害薬による治療
JP2023052188A (ja) 消化管疾病のｊａｋ阻害薬による治療
JP2022177262A5 (enExample)
JP7150723B2 (ja) 消化管疾病のインテグリン阻害薬による治療
JP2020513280A (ja) 消化管疾病の免疫抑制剤による治療
EP3810268A1 (en) Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20200094031A1 (en) Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US20240335644A1 (en) Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11134889B2 (en) Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
JP2020515579A (ja) 消化管疾病の生菌生物学的製剤による治療
WO2018183932A1 (en) Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2018112237A1 (en) Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230301

R150 Certificate of patent or registration of utility model

Ref document number: 7237834

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150